Lexicon Pharmaceuticals Inc
NASDAQ:LXRX

  • LAST PRICE
    0.9752
  • TODAY'S CHANGE (%)
    -0.0848 (-8.0000%)
  • Bid / Lots
    0.9810/ 1
  • Ask / Lots
    0.9900/ 5
  • Open / Previous Close
    1.0800 / 1.0600
  • Day Range
    0.9703
    1.0800
  • 52 Week Range
    0.9703
    3.7300
  • Volume
    5,418,269

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
LXRX
Lexicon Pharmaceuticals Inc
352.5M
-1.3x
---
CMPS
Compass Pathways PLC
344.8M
-2.3x
---
NWBO
Northwest Biotherapeutics Inc
365.9M
-4.4x
---
XOMA
XOMA Royalty Corp
353.6M
-9.9x
---
ENGN
enGene Holdings Inc
337.4M
-1.6x
---
DSGN
Design Therapeutics Inc
328.4M
-6.9x
---
As of 2024-11-16

Company Information

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The Company pipeline includes INPEFA (sotagliflozin), LX9211, and LX9851. Sotagliflozin is an orally delivered small molecule compound that is being developed for the treatment of heart failure and type I diabetes, and type II diabetes mellitus, chronic kidney disease and other cardiovascular risk factors. LX9211 is an orally delivered small molecule compound that is being developed for the treatment of neuropathic pain. The Company is conducting a Phase II clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase II clinical trial of LX9211 in post-herpetic neuralgia. The Company is conducting preclinical development of LX9851, an orally delivered small molecule drug candidate, as a treatment for obesity and tool for weight management.

Contact Information

Headquarters
2445 Technology Forest Blvd, 11Th FloorTHE WOODLANDS, TX, United States 77381
Phone
281-863-3000
Fax
281-863-8088

Executives

Independent Chairman of the Board
Raymond Debbane
Chief Executive Officer, Director
Michael Exton
Executive Vice President - Innovation and Chemical Sciences
Alan Main
Senior Vice President, General Counsel
Brian Crum
Senior Vice President and Chief Commercial Officer
Thomas Garner

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$352.5M
Revenue (TTM)
$5.2M
Shares Outstanding
361.5M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.20
EPS
$-0.75
Book Value
$0.38
P/E Ratio
-1.3x
Price/Sales (TTM)
67.4
Price/Cash Flow (TTM)
---
Operating Margin
-4,037.43%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.